MARKET

TRVN

TRVN

Trevena Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2625
+0.0150
+6.06%
Opening 11:04 05/27 EDT
OPEN
0.2598
PREV CLOSE
0.2475
HIGH
0.2669
LOW
0.2502
VOLUME
334.98K
TURNOVER
62.35K
52 WEEK HIGH
2.200
52 WEEK LOW
0.1805
MARKET CAP
43.45M
P/E (TTM)
-0.7430
1D
5D
1M
3M
1Y
5Y
Trevena to Present at the H.C. Wainwright Global Investment Conference
CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that...
GlobeNewswire · 05/18 20:05
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Okyo Pharma Ltd. ADR (NASDAQ: OKYO) gained 30% to $5.20 as the company priced its IPO at $4 per ADS.
Benzinga · 05/17 16:00
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 05/17 08:49
--HC Wainwright Lowers Trevena's Price Target to $3.50 From $5, Maintains Buy Rating
MT Newswires · 05/12 13:19
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Trevena stock falls 30% as Q1 net loss widens Y/Y
Trevena (NASDAQ:TRVN) stock fell ~30% on May 11 after the company reported its Q1 results. Net loss widened to -$16.39M, compared to -$9.84M in Q1 2021 Total revenue declined to
Seekingalpha · 05/11 14:59
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates
Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 12:15
More
No Data
Learn about the latest financial forecast of TRVN. Analyze the recent business situations of Trevena Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
75.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TRVN stock price target is 3.167 with a high estimate of 4.000 and a low estimate of 2.000.
High4.000
Average3.167
Low2.000
Current 0.2780
EPS
Actual
Estimate
-0.08-0.06-0.04-0.02
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 106
Institutional Holdings: 33.95M
% Owned: 20.51%
Shares Outstanding: 165.52M
TypeInstitutionsShares
Increased
15
978.90K
New
8
1.00M
Decreased
31
3.45M
Sold Out
10
457.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Leon Moulder
President/Chief Executive Officer/Director
Carrie Bourdow
Chief Financial Officer/Senior Vice President
Barry Shin
Senior Vice President
Mark Demitrack
Senior Vice President
Robert Yoder
Other
Patricia Drake
Independent Director
Scott Braunstein
Independent Director
Michael Dougherty
Independent Director
Marvin Johnson
Independent Director
Jake Nunn
Independent Director
Anne Phillips
Independent Director
Barbara Yanni
No Data
No Data
About TRVN
Trevena Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. It is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. It is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. It is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine.

Webull offers kinds of Trevena Inc stock information, including NASDAQ:TRVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TRVN stock methods without spending real money on the virtual paper trading platform.